2008-09 CPDC Annual Report – English
2008-09 CPDC Annual Report – French
Reports
About CPDC
Did you know?
CPDC is one of Ontario’s largest manufacturers of Fludeoxyglucose – the world’s most widely used PET imaging probe.
Learn MoreMolecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.
Learn More
-
The half-life of the fluorine-18 isotope, used to make many PET probes, is only 109.8 minutes. In about a day, the isotopes injected into a patient have either been excreted or have completed their decay.
-
In the last three years, CPDC has introduced three new molecular probes to Ontario for clinical trials in disease diagnosis and drug development.
Learn More
-
CPDC’s Investigator Sponsored Research Program helps researchers move discoveries in molecular probe technology from the lab to the clinic.
Learn More
-
CPDC, along with a national team of experts, is working to develop alternative, non-reactor based sources of medical isotopes to ensure adequate supplies for Canadians.
Learn More
-
CPDC is developing several “orphan probes” to help our health care system diagnose and treat thousands of patients in Canada suffering from certain rare diseases.
-
CanProbe is a new joint-venture company formed by CPDC and University Health Network to meet increasing Canadian and global demand for molecular probes.
Learn More
-
Molecular probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
Learn More
-
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
Learn More
-
During the recent shortage of medical isotopes, CPDC provided substitutes for use in bone scans and imaging kidney function.
Learn More
-
• Over 200 professionals in medical imaging attend CPDC’s Annual Probe Development Workshop to learn about the latest advances in research and application of molecular probes.
Learn More
